Inclusion Criteria:

- Prior confirmed histological diagnosis of prostatic carcinoma.

- Rising PSA while receiving hormonal therapy or after surgical castration defined as 2
sequential increases above a previous lowest reference value within the past 12
months; PSA must be at least 4ng/ml at the time of study entry.

- No distant metastases as evidenced by bone scan (+ or - centered X-Ray or MRI), and
spiral thoracoabdominopelvic CT scan.

- Effective castration throughout the study. Any prior anti-androgen therapy should be
stopped with documented continued elevation of PSA 4 weeks after the cessation of
flutamide (6 weeks for bicalutamide).

- Serum testosterone levels < 50ng/dL at the time of progression and throughout the
study.

- Age > or = to 18 years.

- Extensive metabolizer by CYP2D6 genotyping.

- Karnofsky Performance Status > or = to 70% and life expectancy > 6 months.

- Adequate hematological, renal and liver function.

- Signed written informed consent

Exclusion Criteria:

- Poor metabolizers by CYP2D6 genotyping.

- Prior palliative radiotherapy or any prior chemotherapy or experimental therapy.

- More than one line of any prior anticancer treatment with estrogen (estrogen or
estramustine) if discontinued at least 4 weeks before study entry.

- Concomitant administration of biphosphonate or chronic corticosteroids.

- Presence of progressive symptoms not adequately controlled with non opioid
medications

- Concomitant use of medications known to be cytochrome P450 2D6 inhibitors as listed
in protocol appendice

- Previous malignancies except if there has been a disease-free interval of at least 5
years and except curatively treated non-melanoma skin cancer

- Other serious illness or medical condition, which would not permit the patient to be
managed according to the protocol.